Reduced acute and late toxicities with intensity-modulated radiation therapy compared to three-dimensional conformal radiation therapy in post-operative gastric cancer
The role of intensity-modulated radiation therapy (IMRT) in post-operative gastric cancer is unknown. We evaluated the toxicity profiles of post-operative gastric cancer patients treated with IMRT or three-dimensional conformal radiation therapy (3D-CRT).
We identified patients with gastric cancer treated with post-operative radiation at our institution between 2002 and 2016. Acute and late toxicities were evaluated per RTOG/EORTC Radiation Toxicity Grading Scale. Statistical analysis was performed using Chi-square tests, t tests, log-rank, and logistic regression.
We identified 66 patients who underwent surgical resection as part of planned definitive treatment. Eighty percent of patients had T3 or higher disease, while 67% had N2+ disease.
Thirty patients received 3D-CRT, while 36 received IMRT. Patients receiving 3D-CRT were younger in age than IMRT, treated longer ago, and did not receive neoadjuvant chemotherapy.
Acute grade 2 lower GI toxicity was higher with 3D-CRT (40% vs 17%, p = 0.04). 3D-CRT had higher rates of late lung toxicity of any grade (23% vs 3%, p = 0.02), grade 3+ late esophageal toxicity (23% vs 3%, p = 0.02), and grade 2+ late intestinal toxicity (19% vs 0% p = 0.01).
Dosimetric analysis showed that keeping Bowel V5 ≤ 93% protected against development of acute lower GI toxicity of any grade, with V5 ≤ 93% resulting in 10.5% incidence, and V5 > 93% resulting in 52% incidence (p = 0.004).
Use of IMRT in post-operative gastric cancer is associated with reduced acute and late toxicities. Consideration should be given for prospective evaluation in the future.
KeywordsGastric cancer Post-operative radiation Intensity modulated Conformal Toxicities
Compliance with ethical standards
This study received no funding.
Conflicts of interest
All authors declare that they have no conflicts of interest. Ashwin Shinde declares that he has no conflicts of interest. Wei-Hsien Hou declares that he has no conflicts of interest. Chunhui Han declares that he has no conflicts of interest. Scott Glaser declares that he has no conflicts of interest. Yanghee Woo declares that she has no conflicts of interest. Joseph Chao declares that he has no conflicts of interest. Jeffrey Wong declares that he has no conflicts of interest. Yi-Jen Chen declares that he has no conflicts of interest.
This article does not contain any studies with animals performed by any of the authors. All procedures performed were in accordance with ethical standards of the institutional review board and consistent with the 1964 Helsinki declaration and its later amendments.
Individualized patient consent for this retrospective review was waived by the institutional review board due to the difficulty with reaching this patient population, as most had either passed away or were lost to follow-up.
- 3.Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730. https://doi.org/10.1056/NEJMoa010187 CrossRefGoogle Scholar
- 4.Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK (2012) Phase III trial comparing Capecitabine plus cisplatin versus Capecitabine plus cisplatin with concurrent Capecitabine radiotherapy in completely resected gastric Cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268–273. https://doi.org/10.1200/JCO.2011.39.1953 CrossRefGoogle Scholar
- 5.Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde C, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for Resectable gastroesophageal Cancer. N Engl J Med 355:11–20. https://doi.org/10.1056/NEJMoa055531 CrossRefGoogle Scholar
- 6.NCCN: Gastric Cancer (2018) Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 01 July 2018
- 8.Wieland P, Dobler B, Mai S, Hermann B, Tiefenbacher U, Steil V, Wenz F, Lohr F (2004) IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol 59:1236–1244. https://doi.org/10.1016/j.ijrobp.2004.02.051 CrossRefGoogle Scholar
- 9.Wang X, Li G, Zhang Y, Bai S, Xu F, Wei Y, Gong Y (2013) Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: Dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT). Med Dosim 38:395–400. https://doi.org/10.1016/j.meddos.2013.04.007 CrossRefGoogle Scholar
- 12.Zhang T, Liang Z-W, Han J, Bi JP, Yang ZY, Ma H (2015) Double-arc volumetric modulated therapy improves dose distribution compared to static gantry IMRT and 3D conformal radiotherapy for adjuvant therapy of gastric cancer. Radiat Oncol 10:114. https://doi.org/10.1186/s13014-015-0420-x CrossRefGoogle Scholar
- 14.Milano MT, Garofalo MC, Chmura SJ, Farrey K, Rash C, Heimann R, Jani AB (2006) Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol 79:497–503. https://doi.org/10.1259/bjr/43441736 CrossRefGoogle Scholar
- 15.Chung HT, Lee B, Park E, Lu JJ, Xia P (2008) Can all centers plan intensity-modulated radiotherapy (IMRT) effectively? An external audit of Dosimetric comparisons between three-dimensional conformal radiotherapy and IMRT for adjuvant Chemoradiation for gastric Cancer. Int J Radiat Oncol 71:1167–1174. https://doi.org/10.1016/j.ijrobp.2007.11.040 CrossRefGoogle Scholar
- 16.Dahele M, Skinner M, Schultz B, Cardoso M, Bell C, Ung YC (2010) Adjuvant radiotherapy for gastric Cancer: a Dosimetric comparison of 3-dimensional conformal radiotherapy, Tomotherapy® and conventional intensity modulated radiotherapy treatment plans. Med Dosim 35:115–121. https://doi.org/10.1016/j.meddos.2009.03.003 CrossRefGoogle Scholar
- 19.Chopra S, Agarwal A, Engineer R, Dora T, Thomas B, Sonawone S, Paul SN, Kannan S, Patil P, Mehta S, Shrivastava SK (2015) Intensity modulated radiation therapy (IMRT) is not superior to three-dimensional conformal radiation (3DCRT) for adjuvant gastric radiation: a matched pair analysis. J Cancer Res Ther 11:623–629. https://doi.org/10.4103/0973-1482.150438 CrossRefGoogle Scholar
- 21.Edge SB, American Joint Committee on Cancer (2010) AJCC cancer staging manual. SpringerGoogle Scholar
- 23.Xu D, Huang Y, Geng Q, Guan Y, Li Y, Wang W, Yuan S, Sun X, Chen Y, Li W, Zhou Z, Zhan Y (2012) Effect of lymph node number on survival of patients with lymph node-negative gastric Cancer according to the 7th edition UICC TNM system. PLoS One 7:e38681. https://doi.org/10.1371/journal.pone.0038681 CrossRefGoogle Scholar
- 24.Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M, van Coevorden F, Vanhoutvin S, Hulshof MCCM, Loosveld OJL, ten Tije A(B)J, Erdkamp FLG, Warmerdam FARM, van der Peet DL, Verheul HMW, Boerma D, Los M, Slot A, Houtsma D, Portielje JEA, Blaisse RJB, Spillenaar Bilgen EJ, Polée MB, Geenen MM, Braak JPBM, Neelis KJ, Slingerland M, Jansen RLH, Buijsen J, Beeker A, Eijsbouts QAJ, van Riel JMGH, Rozema T, van Spronsen DJ, Meerum Terwogt JM, Tanis BC, van der Torren-Conze AME, van Hilligersberg R, Koopman M, den Boer MO, Creemers GJ, van der Sangen M, Rentinck MEM, van den Berg HP, Jonkers GJPM, Grootenboers D, Vulink AJE, Hovenga S, van der Mijle HCJ, Baars A, Haringhuizen AW, Appels MIE, Rietbroek RC, Hendriksen EM, Legdeur MCJC, ten Bokkel Huinink D, van Dobbenburgh OA, Smit JM, van Bochove A, Veldhuis GJ, Muller EW, Bonenkamp J(H)J, Braam PM, de Boer J, van Halteren HK, Valster FAA, Imholz ALT, van Dijk MA, van der Gaast A, Otten J(H)MMB, Ceha HM, Glimelius B, Lagerbäck C, Perman M, Johnsson A, Borg D, Nielsen NH, Piwowar A, Elmlund M, Hörberg H, Edlund P, Johansson B, Flygare P, Jespersen ML (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 0:616–628. https://doi.org/10.1016/S1470-2045(18)30132-3 CrossRefGoogle Scholar